STRC Research

STRC OTOA Paralog Cross-Rescue

5 min read

STRC OTOA Paralog Cross-Rescue

Otoancorin (OTOA) is stereocilin’s closest paralog — both are ZP-domain-containing, extracellular, GPI-anchored, tectorial-membrane-binding scaffolding proteins. OTOA is expressed in cochlear supporting cells and anchors the TM to non-sensory epithelium. Pharmacologically upregulating OTOA (or delivering an engineered OTOA variant) could recruit it to OHC stereocilia and provide a STRC-independent TM anchor.

The hidden assumption this breaks

Gene therapy presumes the missing gene is uniquely essential. But mammalian genomes carry silent redundancy — paralogs with related function, typically expressed in different cells. Rescue via paralog activation has succeeded for other systemic diseases (HbF reactivation for sickle-cell, utrophin upregulation for Duchenne). No one has asked the question for DFNB16.

Why OTOA is the right candidate

  • Shared architecture: both STRC and OTOA have ZP-like C-terminal modules, GPI anchors, multiple disulfide-rich extracellular domains.
  • Shared function: both attach TM to cellular surface (OTOA to supporting epithelium; STRC to OHC stereocilia).
  • Same chromosome region (~chr15q15 — though OTOA is actually on chr16p12.2; original note checked). Re-check coordinates — OTOA is on 16p12.2, STRC on 15q15.3. Not adjacent. Still paralogous.
  • OTOA loss → DFNB22 — recessive hearing loss with TM detachment. Protein is critical and the machinery to express it exists in cochlea.

Three avenues

Avenue 1 — Transcriptional upregulation of endogenous OTOA in OHC

Identify transcription factors that drive OTOA in supporting cells; repurpose via CRISPRa (dCas9-VP64) targeted to OTOA promoter, delivered with OHC-specific B8 enhancer. Forced OTOA expression in OHC → OTOA secreted at OHC surface → OTOA self-inserts into TM with its GPI anchor → provides synthetic STRC substitute.

Avenue 2 — Delivery of engineered OTOA variant (OTOA-HTC)

OTOA has a TM-side anchor domain. STRC has both a TM anchor domain AND inter-stereocilia (HTC) domains. Engineer OTOA-HTC = OTOA scaffold + STRC’s HTC-forming extracellular region grafted in. Delivered via AAV with B8 enhancer → OHC expresses the chimera → it goes to TM interface AND forms HTCs.

Avenue 3 — Small molecule that extends supporting-cell OTOA expression to nearby OHCs

Pharmacological activation of transcription factors whose natural gradient includes OHCs at the margin. Much weaker specificity, but drug-level delivery.

Computational proof path

  1. Transcriptomic audit — mine SHIELD (Shared Harvard Inner Ear Laboratory Database), Kelley lab single-cell data, and ENCODE for OTOA expression in adult OHCs. Hypothesis: low but non-zero baseline (TPM 0–5). If TPM ≥ 1, avenue 1 is attractive (modest upregulation needed). Not yet run.
  2. Sequence alignment STRC × OTOA — ✅ Phase 1A complete 2026-04-20 → STRC OTOA Paralog Phase1A Sequence Audit. Global identity 28.3%, ARM-region 33.8%, sequence-level paralog confirmed. Two pharmacophore anchors (F1646→F1014, E1659→E1027) identically conserved.
  3. AF3-Multimer engineered OTOA chimera × TMEM145 GOLD — PAUSED after Phase 1B below. Chimera grafting requires shared fold; fold diverged.
  4. Structural superposition STRC × OTOA — ✅ Phase 1B complete 2026-04-20 → STRC OTOA Paralog Phase1B Structure Alignment. ARM-region Cα RMSD 13.78 Å — paralog at sequence level, NOT at fold level. Chimera avenue collapses; upregulation avenue weakened.
  5. Transcription factor enrichment for OTOA promoter — ChEA3 / ENCODE ChIP-seq motif analysis. Identify TFs co-expressed in OHCs (prestin-expressing cells) with OTOA regulatory capacity. Candidate: GATA3, POU4F3, MYO7A downstream TFs. Not yet run; conditional on Avenue 1 remaining viable after transcriptomic audit.
  6. Feasibility of B8-driven OTOA — OTOA CDS is 3,462 bp (1,153 aa, UniProt Q7RTW8). Fits in AAV with B8 enhancer (587) + polyA (250) + ITRs (290) = 4,589 bp. Headroom: 111 bp. Tight but feasible.
  7. Cross-species OTOA conservation — confirm OTOA is intact in human and retains all domains (no pseudogene issue like STRCP1 for STRC). Not yet run.

Risks and open questions

  • Forced OTOA in OHC may mislocalize (OTOA relies on supporting-cell-specific secretion/assembly machinery).
  • OTOA-STRC chimera confirmed problematic after Phase 1B — folds have diverged even though sequence shares 28-34% identity. A clean graft will not work; de novo interface engineering required.
  • Unknown whether OTOA can form HTC-like inter-stereocilia crosslinks. STRC forms HTCs because of specific inter-repeat surfaces; OTOA may lack this capacity. Need AF3-Multimer of OTOA homo-oligomer to check.
  • DFNB22 patients (OTOA-deficient) may have elevated STRC as compensation; reverse check this hypothesis against published OTOA-/- transcriptomes.
  • F1646 / E1659 identical conservation in OTOA is a side-product finding: these residues are load-bearing in both paralogs. Useful as a pathogenicity marker (ClinVar interpretation support).

Why it is still worth the compute cost

Even if Avenue 2 (chimera) requires engineering, the transcriptomic audit (Step 1) is a single afternoon of data mining and answers whether this idea is dead or alive. Cheapest possible filter for a high-novelty hypothesis.

Status summary (post-Phase 1B, 2026-04-20)

AvenueStatusNext gate
1. OTOA upregulation in OHCWeakened; alive only if native OTOA fold can substituteTranscriptomic audit (TPM in adult OHCs); TM-align rerun
2. OTOA-STRC chimeraKilled as simple graftDo not pursue without sub-paralog proof-of-concept
3. Small-molecule OTOA activatorUnchangedRequires promoter-screen program, higher-cost
Side-finding: F1646/E1659 paralog conservationNewUseful for ClinVar-style interpretation; feeds back into STRC Electrostatic Analysis E1659A

Connections

Graph View

Backlinks